Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases.
The financing round was led by GIC Private Limited, and participants included new investors such as China Life Private Equity Investment Company and Vertex Ventures, as well as Series A investors AdvanTech and Legend Capital.
In December 2016, Harbour BioMed was founded through gathering $50m series A financing and acquiring Netherlands-based fully human transgenic antibody technology firm Harbour Antibodies BV and its subsidiaries.
The firm has incorporated Harbour Mice technologies into its novel antibody technology and discovery biology, preclinical and clinical development operations.
Harbour BioMed also signed multiple license and collaboration agreements for its Harbour Mice, and created advanced therapeutic pipeline based on internal discovery and in licensing activities.
Earlier this year, Harbour gathered funding under A+ round carried out by CDH and AdvanTech to support its in-licensed clinical programs for Greater China.
Harbour’s development programs comprised of an anti-FcRn based antibody against multiple autoimmune diseases, including myasthenia gravis and neuromyelitis optica, and biologic against inflammatory dry-eye disease.
Last year, the company secured rights for these assets and developing them for the Greater China market.
Recently, the company also filed two INDs for three different indications in China, which will allow to carry out clinical studies.
Harbour’s development programs also include CD3-based bi-specific antibody therapy against Her-2 overexpressed cancer and anti-PD-L1 antibody for the treatment of multiple solid tumors and hematological cancers.
Harbour BioMed founder, chairman and CEO Dr Jingsong Wang said: “During the one and half years since we established operations, Harbour has successfully expanded its network of collaborations for its core transgenic mouse technologies, rapidly built an innovative pipeline through internal discovery and in-licensed development stage programs in the areas of oncology and immunology, and established an experienced and professional team.
“The financing is a very strong vote of confidence by our new and existing investors in our vision for the company, strategy, progress to date and our team.”